Peloton recalls 833,000 more bikes over seat post issue, two injuries reported

Peloton recalls 833,000 more bikes over seat post issue, two injuries reported


The entrance to the Peloton offices in Midtown Manhattan.

Erik Mcgregor | Lightrocket | Getty Images

Peloton is recalling its original Bike+ after receiving reports that the seat post broke and detached from the equipment during use, leading to two injuries, the Consumer Product Safety Commission said in a news release Thursday. 

The recall impacts 833,000 units, touching every original Bike+ the company has ever sold. The bikes were sold between January 2020 and April 2025 but Peloton stopped manufacturing them in 2022. 

The recall comes after Peloton received two reports of injuries “due to a fall” after the post broke off, the CPSC said in its release. It received three reports in total about the issue.  

The CPSC said consumers should immediately stop using the bikes and contact Peloton for a free repair. The company is offering a free seat post that users can install at home, the agency said. 

In a statement Thursday, Peloton said, “The integrity of our products and our Members’ well-being are our top priorities.” The company encouraged users to request the new part “as soon as possible.”

The notice Thursday marks the second time Peloton has had to recall one of its bike models due to issues with the seat post. 

In May 2023, the company recalled every base Bike model that it ever sold, totaling 2.2 million units, after receiving 35 reports of the seat post breaking and detaching during use. The issue led to 13 injuries, including a fractured wrist, lacerations and bruises.

At the time, the company said the recall led to higher than expected membership churn, as between 15,000 and 20,000 people paused their monthly subscriptions while waiting for the seat post to be replaced. Replacing the parts cost at least $40 million during its fiscal 2023 fourth quarter, the company said at the time. 

The recall Thursday, the fifth since Peloton’s founding, comes as CEO Peter Stern looks to get the fitness company back to growth and move past the many issues it has faced since its founding. 

Changing consumer dynamics have plagued the company since the end of the Covid-19 pandemic, but so have its recalls, including one for its Tread+ treadmill in 2021 after a child was killed. 

Just over a month ago, Peloton relaunched its product assortment, raised prices and unveiled new features ahead of the crucial holiday shopping season. 

The current quarter is Peloton’s biggest for hardware sales. 

The company is expected to report first quarter fiscal 2026 earnings after the bell on Thursday.



Source

U.S. counterterrorism director Joe Kent resigns over war: ‘Iran posed no imminent threat’
World

U.S. counterterrorism director Joe Kent resigns over war: ‘Iran posed no imminent threat’

Joe Kent, director of the National Counterterrorism Center, testifies during the House Homeland Security Committee hearing titled “Worldwide Threats to the Homeland,” in Cannon building on Wednesday, December 11, 2025. Tom Williams | Cq-roll Call, Inc. | Getty Images National Counterterrorism Center Director Joe Kent on Tuesday announced he will resign in response to the […]

Read More
European markets need to get their act together, CEO of Norway’s  trillion wealth fund says. ‘The winner takes it all’
World

European markets need to get their act together, CEO of Norway’s $2 trillion wealth fund says. ‘The winner takes it all’

Nicolai Tangen, chief executive officer of NBIM, at the Norges Bank Climate Conference in Oslo, Norway, on Oct. 21, 2025. Naina Helén Jåma | Bloomberg | Getty Images European markets are facing a crisis and must get their act together to fix it, the head of the world’s biggest individual investor has said. Speaking to […]

Read More
Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market
World

Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market

HSBC analysts just slashed their recommendation on the world’s most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to dominate market narratives of the sector. Analysts led by Rajesh Kumar downgraded Lilly to Reduce from Hold, cutting their target price to $850 from $1,070, […]

Read More